Home GCC Ronaldo invests in healthtech firm Bioniq; firm’s valuation hits $82m Combining advanced blood biomarker analysis and self-reported health data, Bioniq creates customised supplements designed to meet individual health needs by Gulf Business October 24, 2024 Image: Supplied Global soccer icon Cristiano Ronaldo has made a significant investment in Bioniq, a personalised nutritional support company, bringing the firm’s total valuation to $82m. Bioniq, founded in 2019, offers customised supplements based on blood biomarker data and self-reported health insights, designed to optimise individual health and performance. Ronaldo, who has been a Bioniq member since 2022 and a regular user of its personalised supplements, stated that his investment aligns with his dedication to health and longevity. “Bioniq has the potential to transform how we care for our bodies and help people reach and maintain peak performance for longer,” Ronaldo said. Bioniq has seen fivefold growth this year The company’s user base grew more than fivefold in 2024, with the company’s products now sold in over 70 countries. The platform uses a patent-pending algorithm to create 100 per cent personalised supplements tailored to each individual’s unique health profile. All of its personalised supplements are Swiss-made, pharmaceutical-grade and utilise precise micro-dosing to address bio-individual needs and deficiencies. Each formula is created specifically for an individual user and features a unique mix of up to 120 antioxidants, vitamins, minerals, phytonutrients, amino acids, and prebiotic fibre. This precision-based approach has garnered partnerships with major sports and health institutions, including UFC and Lanserhof, and is the preferred choice of many top athletes. Ronaldo’s involvement is expected to drive the company’s global expansion, particularly in the US, Europe and the Middle East. The US market already accounts for over 60 per cent of the company’s global sales. “Cristiano Ronaldo is the perfect partner and shareholder. His personal experience with Bioniq reinforces his belief in what we’re building,” said Vadim Fedotov, the health tech firm’s co-founder and CEO. The investment follows Bioniq’s successful Series B funding round, which raised $15m from European VCs HV Capital and Unbound.